Geode Capital Management LLC reduced its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 6.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 399,046 shares of the biopharmaceutical company’s stock after selling 26,998 shares during the period. Geode Capital Management LLC owned approximately 0.89% of Vanda Pharmaceuticals worth $6,065,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in VNDA. Cortina Asset Management LLC increased its holdings in Vanda Pharmaceuticals by 81.9% in the 4th quarter. Cortina Asset Management LLC now owns 386,477 shares of the biopharmaceutical company’s stock valued at $5,874,000 after acquiring an additional 173,974 shares during the last quarter. BlackRock Inc. grew its stake in shares of Vanda Pharmaceuticals by 2.4% in the 4th quarter. BlackRock Inc. now owns 4,568,159 shares of the biopharmaceutical company’s stock worth $69,436,000 after buying an additional 106,228 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Vanda Pharmaceuticals by 112.2% in the 3rd quarter. Wells Fargo & Company MN now owns 151,693 shares of the biopharmaceutical company’s stock worth $2,715,000 after buying an additional 80,209 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth $1,031,000. Finally, Cadence Capital Management LLC grew its stake in shares of Vanda Pharmaceuticals by 74.2% in the 4th quarter. Cadence Capital Management LLC now owns 109,074 shares of the biopharmaceutical company’s stock worth $1,658,000 after buying an additional 46,468 shares in the last quarter. Institutional investors own 81.04% of the company’s stock.
In related news, insider Mihael Hristos Polymeropoulos sold 60,966 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $18.72, for a total transaction of $1,141,283.52. Following the completion of the transaction, the insider now directly owns 1,243,838 shares of the company’s stock, valued at approximately $23,284,647.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO James Patrick Kelly sold 8,532 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $18.72, for a total transaction of $159,719.04. Following the transaction, the chief financial officer now directly owns 208,066 shares of the company’s stock, valued at $3,894,995.52. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 78,023 shares of company stock valued at $1,460,591. 7.60% of the stock is owned by corporate insiders.
VNDA stock opened at $15.05 on Tuesday. Vanda Pharmaceuticals Inc. has a 12 month low of $11.90 and a 12 month high of $20.40. The stock has a market cap of $761.62, a P/E ratio of -43.00 and a beta of 1.13.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative net margin of 9.43% and a negative return on equity of 11.94%. The firm had revenue of $44.28 million during the quarter, compared to analysts’ expectations of $44.00 million. During the same period in the previous year, the company earned $0.08 EPS. The firm’s revenue for the quarter was up 15.8% compared to the same quarter last year. analysts predict that Vanda Pharmaceuticals Inc. will post -0.09 earnings per share for the current year.
VNDA has been the subject of a number of recent research reports. Oppenheimer reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 8th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. ValuEngine raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Jefferies Group reissued a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, February 13th. Finally, Seaport Global Securities initiated coverage on shares of Vanda Pharmaceuticals in a research note on Friday, January 19th. They issued a “buy” rating and a $20.00 price objective for the company. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $21.67.
TRADEMARK VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/17/geode-capital-management-llc-trims-holdings-in-vanda-pharmaceuticals-inc-vnda.html.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.